Nephronophthisis (NPH), a recessive cystic kidney disease, is the most frequent genetic cause for end-stage renal disease in the first two decades of life. Mutations in three genes (NPHP1, 2, and 3) were identified as causative. Extrarenal manifestations are known, such as retinitis pigmentosa (Senior-Løken syndrome, SLS) and ocular motor apraxia type Cogan. Recently, we identified a novel gene (NPHP4) as mutated in NPH. To date, a total of only 13 different NPHP4 mutations have been described. To determine the frequency of NPHP4 mutations, we performed mutational analysis by direct sequencing of all 30 NPHP4 exons in 250 different patients with isolated NPH, SLS, or Cogan syndrome ascertained worldwide over 14 years. We identified 23 novel NPHP4 sequence variants in 26/250 different patients (10%). Interestingly, we detected homozygous or compound heterozygous mutations of NPHP4 in only 6/250 different patients (2.4%), but only one heterozygous NPHP4 sequence variant in 20/250 different patients (8%). In the six patients with two NPHP4 mutations, 5/8 mutations (63%) were likely loss-of-function mutations, whereas in the 20 patients with only one sequence variant, only 1/20 (5%) was a likely loss-of-function (i.e., truncating) mutation. We conclude that: i) two recessive mutations in NPHP4 are a rare cause of nephronophthisis; ii) single heterozygous NPHP4 sequence variants are three times more prevalent than two recessive mutations; iii) there is no genotype/phenotype correlation; iv) there must exist further genes causing nephronophthisis, since in 224/250 (90%) patients, no sequence variants in either of the four NPH genes were detected.
INTRODUCTION
Nephronophthisis (NPH) is an autosomal recessive cystic kidney disease that represents the most common genetic cause for end-stage renal disease in children and young adults (Hildebrandt et al., 2001) . NPH leads to end-stage renal disease at a median age of 13 years. Characteristic renal histology shows a triad of renal interstitial fibrosis, DOI: 10.1002/humu.9326 interstitial cell infiltrates, and tubular atrophy with cyst development at the corticomedullary junction (Waldherr et al., 1982) . NPH is a genetically heterogenous disorder. Four genes have been identified: Recessive mutations in NPHP1 cause NPH type 1 (juvenile onset) (MIM# 256100) (Hildebrandt et al., 1997 , Saunier et al., 1997 . Its gene product nephrocystin (NPHP1) is a novel docking protein that plays a role in signaling at adherens junctions and focal adhesions of renal epithelial cells. Mutations in the NPHP2 gene encoding inversin cause NPH type 2 (infantile onset) (MIM# 602088) (Haider et al., 1998 . Mutations in NPHP3 and its gene product nephrocystin-3 are responsible for NPH type 3 (adolescent form) (MIM# 604387, 608002) (Olbrich et al., 2003 , Omran et al., 2000 . Finally, we have identified mutations in NPHP4 encoding nephrocystin-4/nephroretinin as causing NPH type 4 (juvenile onset) (MIM# 607215, 606966, 606996) (Mollet et al., 2002 . With the exception of inversin, the NPH-causing genes represent novel genes. Recent evidence demonstrated expression of all 4 genes (NPHP1-4) in primary cilia of renal epithelial cells, a feature that has been recognized for virtually all proteins which, if defective give rise to renal cystic disease in mice or humans (Watnick et al., 2003) . The gene products of the NPHP2, 3 and 4 genes bind to nephrocystin, the gene product of the NPHP1 gene (Mollet et al., 2002) . A number of extrarenal manifestations can be associated with NPH, such as retinitis pigmentosa (Senior-Løken syndrome, SLS) (Loken et al., 1961 , Senior et al., 1961 , ocular motor apraxia (Cogan syndrome) (Betz et al., 2000 , Mollet et al., 2002 , or liver fibrosis (Boichis et al., 1973) . Retinitis pigmentosa is associated with NPH in about 10% of cases (Caridi et al., 1998) . So far no genotype/phenotype correlation regarding the type of NPHP gene mutated or regarding distinct mutated alleles of these genes have been detected. The recently identified NPHP4 gene extends over 130 kb, consists of 30 exons, and encodes 1426 amino acids. NPHP4 is strongly conserved in evolution, with 23% amino acid identity in a protein of C. elegans (Mollet et al., 2002 . So far only 13 different mutations in NPHP4 have been reported in 17 different patients (Mollet et al., 2002 .
To determine the frequency of NPHP4 mutations in a large cohort of patients with NPH, we here performed mutational analysis by direct sequencing of all 30 exons of NPHP4 in 250 unrelated NPH patients. We identified 23 novel NPHP4 sequence variants in 26 unrelated patients with NPH. We detected both recessive mutations of NPHP4 in only 6/250 different patients (2.4%), whereas we detected only one heterozygous NPHP4 sequence variant in 20/250 different patients. From these data we conclude, i) mutations in NPHP4 are a rare cause (2.4%) of nephronophthisis; ii) there is no genotype/phenotype relationship regarding extrarenal manifestations; iii) there must exist further genes causing nephronophthisis.
PATIENTS AND METHODS

Patients
For mutation screening in NPHP4 we selected from a cohort of 375 patients with NPH on the basis of DNA availability 250 unrelated patients with at least one child affected by isolated NPH, SLS or Cogan syndrome. The diagnostic criteria were as follows: i) characteristic clinical phenotype of NPH, SLS or Cogan syndrome, as established by a pediatric nephrologist using a standard clinical questionnaire (www.renalgenes.org); ii) renal ultrasound or a renal biopsy result compatible with NPH; iii) exclusion of a homozygous deletion in NPHP1; iv) pedigree compatible with autosomal recessive inheritance. Renal biopsy result was considered characteristic for NPH if there was disruption of tubular basement membranes, tubulointerstitial round cell infiltration and fibrosis, and tubular atrophy with microcyst development (Waldherr et al., 1982) . Renal ultrasound was considered characteristic for NPH if there was increased echogenicity with loss of corticomedullary differentiation or presence of corticomedullary cysts. Origin of patients was worldwide with an emphasis on European descent. We obtained blood samples, pedigrees, and clinical information following informed consent (www.renalgenes.org). To assess the genetic data about the frequency of NPHP4 mutations, we evaluated only one sibling per family. This cohort of 250 unrelated patients consisted of 190 patients with isolated NPH (76%), 50 patients with SLS (20%), and 10 patients with Cogan syndrome (4%). Consanguinity was present in 9/190 NPH patients (5%), 6/50 SLS patients (12%), and in 1/10 patients with Cogan syndrome (10%). The diagnosis of NPH was confirmed by renal biopsy in 61/190 NPH patients (32%), 4/50 SLS patients (8%), and 1/10 patients with Cogan syndrome (10%). For all patients we had previously excluded a homozygous deletion of NPHP1, a combination of a heterozygous NPHP1 deletion with a heterozygous NPHP1 point mutation, and mutations in NPHP3. The diagnosis of infantile NPHP (NPHP2) was excluded by absence of the NPHP2-specific criterion of end-stage renal disease occurring within the first 5y of life.
Mutational analysis
Genomic DNA was extracted from blood samples using the QIAGEN Blood & Cell Culture DNA kit according to the manufacturer's instructions (Qiagen, Valencia, CA). For one individual from each family (250 patients) direct sequencing was performed for all 30 NPHP4 exons on both strands using the dideoxy chain termination method on an ABI capillary sequencer. Resulting sequences were aligned and analyzed with the Sequencher™ software (Gene Codes Corporation, Ann Arbor, MI) and Mutation Surveyor™. Primers flanking the 30 exons of NPHP4 were derived from genomic sequence, using the program PRIMER3 (http://zeon.well.ox.ac.uk/gitbin/primer3_www.cgi) (GenBank accession no. NT_015102, which corresponds to the published cDNA and amino acid sequences. Numbering is based on cDNA sequence. Position +1 corresponds to the A of the ATG translation initiation codon in the reference sequence. Mollet et al., 2002 . Primer sequences are available from the authors. For segregation analyses parental DNA, if available, was tested by direct sequencing. For mutational screening of healthy control individuals we employed allele-specific restriction digests, denaturing high-performance liquid chromatography (Transgenomic Wave™), or direct sequencing, as appropriate. For all patients with sequence variants in NPHP4 direct sequencing was performed for all 17 exons of NPHP2 on one strand using the dideoxy chain termination method on an ABI capillary sequencer.
RESULTS
In a cohort of 250 unrelated patients with NPH, SLS or Cogan syndrome, we performed mutational analysis by direct sequencing of both strands for all 30 exons of NPHP4 (a total of 15,000 sequences). We detected altogether 23 different novel NPHP4 sequence variants in a total of 26/250 unrelated patients (10%) ( Table 1 ). However, in only 6/250 families (2.4%) we detected both mutated alleles, i.e. two heterozygous mutations or one homozygous mutation of NPHP4 (Table 1) . Most mutations were truncating mutations. Both missense mutations detected in F720 are conserved in Nphp4 of mouse and nph-4 of C. elegans. In contrast, in 20/250 families (8%) we found only a single heterozygous sequence variant of NPHP4 (Table 1 ). All sequence variants were novel, i.e. they have not been reported previously (Mollet et al., 2002 . All mutations were absent from at least 86 healthy control individuals and were not previously described as polymorphisms (Table 2) . A total of 224/250 (90%) patients did not show any sequence variant in NPHP4. The total of 26 sequence variants consisted of 23 different novel sequence variants (Table 1) . Of the patients, in whom only one sequence variant was found, 4 patients shared a mutation with at least one other patient (F270 with F1015, F94 with F726, F306 with F567, and F491 with F736). Of the patients in whom both NPHP4 mutations were found, only 1 patient shared a mutation (F720 with F534) (Table 1 ). All shared sequence variants were missense. For none of the patients with NPHP4 sequence variants parental consanguinity was reported. In the 3 families with 2 affected children the 2 recessive mutations and 1 single heterozygous sequence variant were present in each of the affected individuals. We also detected 6 additional new polymorphisms in NPHP4, that were at least detected once in > 86 healthy control individuals (Table 3 ). We thus identified 23 different novel NPHP4 sequence variants in 26 unrelated families.
In the 6 families where both NPHP4 mutations were detected (Table 1) , 5 of the 8 different mutations detected (63%) were truncating mutations (nonsense or frame shift). In contrast, in the 20 families with only one heterozygous NPHP4 sequence variant, only 1/20 mutations (5%) was a truncation mutation (c.1839_1840insGA), whereas the others were missense sequence variants (Table 1) . Thus, the likelihood to detect a truncating mutation in patients with two mutated NPHP4 alleles was 12.6 times as high (63% vs. 5%) as in patients with only one heterozygous sequence variant. Although the sequence variants identified as single heterozygous missense changes were absent from > 86 healthy controls, we cannot exclude that they might represent innocuous polymorphisms.
The presence or absence of extrarenal manifestation (retinitis pigmentosa, Cogan syndrome, hearing loss, or chronic bronchitis) did not correlate with either, i) the position of a mutation within the nephrocystin-4/nephroretinin sequence; ii) the type of mutation (truncating vs. non-truncating) or; iii) the fact whether both or only one NPHP4 sequence variant was found (Table 1) . het, heterozygous mutation; hom, homozygous mutation; sm, single mutation; numbering based on cDNA, Position +1 corresponds to the A of the ATG translation initiation codon in the reference sequence NM_015102; b OA, ophthalmologic abnormalities (unspecified); RP, retinitis pigmentosa (Senior-Løken syndrome). (Mollet et al., 2002) a The term polymorphism was used if the sequence variant was detected in at least 1 out of >172 chromosomes from healthy control individuals; numbering based on cDNA, Position +1 corresponds to the A of the ATG translation initiation codon in the reference sequence NM_015102. Table 2 ). Truncating mutations are shown in red. The extent of the truncation is shown beneath the exon structure.
DISCUSSION
By positional cloning we and others have recently identified NPHP4 as a novel gene which, if mutated, causes NPH (Mollet et al., 2002 . In order to determine the frequency and the character of mutations in NPHP4, we here performed mutational analysis in 250 unrelated NPH patients with and without extrarenal manifestations. We detected 23 different novel NPHP4 sequence variants in 26 NPH families. Interestingly, we detected homozygous or compound heterozygous mutations of NPHP4 in only 6/250 families (2.4%), whereas we detected only one heterozygous NPHP4 sequence variant in 20/250 families (8%). Our data indicate that: i) recessive mutations in NPHP4 are a rare cause (2.4%) of nephronophthisis; ii) the presence of a single heterozygous NPHP4 sequence variant is 3.3 times more prevalent than the presence of 2 recessive NPHP4 mutations; iii) a genotype/phenotype correlation was not detected for the presence or absence of extrarenal manifestation; iv) and, there must exist further genes causing nephronophthisis, since in 224/250 (90%) patients no mutation in either of the four NPH genes was detected.
When examining a total of 515 unrelated NPH patients with and without extrarenal manifestations we had detected homozygous NPHP1 deletions in 130 patients (25.2%) (Hoefele et al., unpublished) . In addition, we found a combination of a heterozygous NPHP1 deletion and a heterozygous NPHP1 point mutation in 10/515 patients (2%) (Hoefele et al., unpublished) . This indicates that in about 27% of all patients with NPH the disease is caused by mutations in NPHP1 and thus represents nephronophthisis type 1. In this study we demonstrate that two recessive mutations in NPHP4 occur in only 2.4% of all NPH cases, thereby showing that NPH type 4 represents a rare cause of NPH with and without extrarenal manifestations. This finding supports the concept that NPH is a disorder that shows extensive genetic locus heterogeneity, and that most likely many additional genes are involved (Mollet et al., 2002) . The finding that in 224/250 (90%) patients no NPHP4 mutation was detected, further supports the notion there must exist additional genes causing NPH. All 23 NPHP4 sequence variants identified in this study have not been described before (Mollet et al., 2002 and are therefore novel. We thus expanded the spectrum of distinct NPHP4 sequence variants from 13 to a total of 35 (Table 2, Fig. 1 ). Although the sequence variants were distributed over all 30 exons of NPHP4, there was a propensity towards the C-terminal part of the protein, since 25/35 (71%) of all sequence variants identified in this study are located within exons 16-30 (Table 2) .
We here observed the finding that the presence of a single heterozygous NPHP4 sequence variant was 3.3 times more prevalent (20/250) than the presence of two NPHP4 mutations (6/250). This is reminiscent of our recent finding in patients with NPH type 3, where 3/9 patients (33%) showed two mutations in NPHP3, whereas 6/9 patients (67%) had only a single NPHP3 sequence variant (Olbrich et al., 2003) . The finding that a single heterozygous NPHP4 sequence variant was 3.3 times more prevalent than a two recessive NPHP4 mutations may be interpreted in a variety of ways:
First, a second mutation may have been missed for technical reasons. We deem this possibility very unlikely, since we employed the optimal method for mutation detection: direct exon sequencing from both strands, yielding excellent sequence quality. In addition, we evaluated sequences by two independent computer programs (Sequencher TM and Mutation Surveyor TM ) and by two independent examiners, which in our experience leads to very sensitive mutation detection. Second, a mutation might be located in a non-exonic region. Although this possibility cannot be ruled out with certainty, this is a rare finding. It would therefore not explain the 3.3 fold higher prevalence of patients with a single sequence variant versus patients in whom both mutated alleles are detected. Third, another potential explanation for the high number of single sequence variants found in NPHP3 and NPHP4 would be the possibility of a dominant effect of these mutations. However, there is no evidence of any clinical signs or symptoms of NPH or extrarenal manifestations in the parents of the 515 NPH patients from our total cohort or in the literature. Fourth, it may well be possible that single heterozygous sequence variants may represent innocuous polymorphisms. Finally, it cannot be excluded altogether, that some of the single heterozygous sequence variants observed may be part of digenic or oligogenic mutations in other NPH-causing genes, as has been described for the related disease Bardet-Biedl syndrome (Badano et al., 2003) .
It is known that in about 10% of all patients with NPH there is an association with retinitis pigmentosa (SLS) (Caridi et al., 1998) . However, to date no correlation has been described for the presence or absence of extrarenal involvement in NPH with respect to the gene involved or with respect to specific allelic mutations. Similarly, in this study we did not detect any evidence for a genotype/phenotype relationship regarding extrarenal manifestations, since extrarenal manifestations (retinitis pigmentosa, Cogan syndrome, hearing loss, or chronic bronchitis) did not correlate with either, i) the position of a mutation within the nephrocystin-4/nephroretinin sequence, ii) the type of mutation (truncating vs. non-truncating) or, iii) the fact whether both or only one NPHP4 sequence variant was found (Table 1) . Nevertheless, further inter-and intrafamilial studies on a higher number of patients with NPHP4 mutations might yield more information on genotype-phenotype correlations in NPH.
